Elaprase
Payments companies reported to CMS as associated with Elaprase. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Elaprase, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Elaprase
These are the largest totals companies reported as associated with Elaprase. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Barbara Burton | Chicago, IL | Clinical Genetics (M.D.) | $19,256.94 |
| Joseph Muenzer | Chapel Hill, NC | Pediatrics | $19,156.94 |
| Alberto Santiago Cornier | Santurce, PR | Clinical Genetics (M.D.) | $16,473.84 |
| Kyrieckos Aleck | Albuquerque, NM | Clinical Genetics (M.D.) | $11,100.51 |
| David Karas | Madison, CT | Sleep Medicine (Pediatrics) | $6,697.03 |
| Deepa Soundara Rajan | Detroit, MI | Pediatrics | $3,152.50 |
| Gustavo Maegawa | New York, NY | Clinical Biochemical Genetics | $3,126.25 |
| Priya Kishnani | Durham, NC | Pediatrics | $2,850.00 |
| Can Ficicioglu | Philadelphia, PA | Clinical Genetics (M.D.) | $2,400.00 |
| Damara Ortiz | Pittsburgh, PA | Clinical Genetics (M.D.) | $2,400.00 |
Prescribed Elaprase?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.